In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


Credit Designation Statement

AACR has designated this live activity for a maximum of 19.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this  live continuing medical education activity must complete the online CME Request for Credit Survey by Thursday, April 28, 2022. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 19.25 Medical Knowledge MOC in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives

The evolution of resistance often leads to treatment failure, but incorporation of Darwinian dynamics to understand this evolution during therapeutic trials remains rare.1 As molecular sequencing and diagnostic techniques continue to advance, opportunities also expand for clinicians and physician scientists to incorporate evolutionary dynamic theories to monitor and adapt patient treatments.2 This understanding and application of evolution dynamics has already demonstrated that resistance can be forestalled through the application of evolutionarily-informed “adaptive” therapies, wherein dosing of standard-of-care targeted therapies is adaptively modulated based on patient response.3 This conference will inform attendees on the most recent advances and knowledge of cancer evolution dynamics.

A major issue in the treatment of cancer is the development of resistance to therapies. The acquisition of therapy resistance is often referred to as an evolutionary process, wherein strong selection pressures imposed by therapies select for emergence of resistant clones via an ecological principle known as “competitive release.” Despite a survey by the American Association of Medical Colleges and the Howard Hughes Medical Institute calling for the incorporation of evolutionary theory as a core competency in medical education1, the coverage is still not commensurate with its importance.2 This can result in a competency gap of clinicians and physician scientists treating cancer patients. This conference will meet the need for practical application of evolutionary theory by providing a venue to synthesize concepts in evolutionary dynamics from basic cancer research into clinical applications.

This conference will be useful to basic, translational and clinical scientists, as well as physicians/practicing oncologists and those engaged in the development of new therapeutics or novel therapeutic schedules. In particular, this conference will be useful to those interested in the ecological understanding of carcinogenesis, the mechanisms of intratumoral heterogeneity and how it contributes to the emergence of therapy resistance, and the use longitudinal use of biomarkers to monitor patient response.

After participating in this CME activity, physicians should be able to:

  1. Explain the complexities and strategies of Darwinian Evolution in Cancer.
  2. Articulate the relevance of Evolutionary Dynamics in carcinogenesis and therapy response.
  3. Evaluate strategies to quantify tumor heterogeneity at baseline and strategies to longitudinally monitor evolutionary dynamics during therapy response.
  4. Identify areas in which evolutionary understanding of cancer could be applied to develop improved interventions for prevention, early detection, and therapy.
  5. Translate Evolutionary Dynamic principles into their own research.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.

Acknowledgment of Financial or Other Support

The AACR gratefully acknowledges the following commercial supporters:

Lead Supporter

AbbVie

Professional Education Grants

Pfizer

Questions about CME?

Please contact the Office of CME at (215) 440-9300 or [email protected].